Traws Pharma, Inc.
Severe listing-compliance risk
The share price is below $1 and the stored reverse-split/listing-risk level is HIGH. No verified reverse-split authorization or announced reverse split is currently recorded. This is a risk signal, not confirmation that Nasdaq has issued a deficiency notice.
TRAW · Price history
Price at last available close
$0.35
−$0.23 (-39.60%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Traws Pharma, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza.
How they make money
Traws Pharma is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel oral small molecule antiviral therapies for respiratory viral diseases, relying on capital raises and potential future government stockpiling or commercial partnerships to fund operations.
Products & services
The company is developing two primary investigational antiviral candidates: Ratutrelvir, an oral Mpro inhibitor for COVID-19, and Tivoxavir marboxil, an oral cap-dependent endonuclease inhibitor for influenza.
Brands & revenue mix
Investigational oral small molecule antiviral targeting COVID-19.
Separate brand revenue is not available in this research.Source
Investigational oral small molecule antiviral targeting influenza.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company utilizes unnamed third-party contract research organizations to conduct clinical trials and preclinical studies.Source
Business relationships & partnerships
- BARDA — The company has initiated dialogue with the Biomedical Advanced Research and Development Authority (BARDA) regarding potential stockpiling and pandemic preparedness initiatives.Source
Competitors
Strengths
- Portfolio of novel oral small molecule antiviral candidatesSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-03-31.
Opportunity Score is currently unavailable; Wall Street Score remains independently validated.
The unavailable Opportunity Score is a separate model output. It must not be substituted with zero or inferred from the company score.
Quarterly revenue fell 100.0% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Diluted weighted-average shares increased 1164.1% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
35
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
47
Weak
Financial Strength
71
Business Quality / Moat
17
Management
80
Growth Quality
18
Risk / Durability
29
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
32
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
45/100
Building Historical Record
Model Score 45/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
Reverse-split / listing-compliance risk: HIGH
This is a risk signal, not a prediction. It is separate from Wall Street Score and does not change the company score. It looks for listing-pressure signals such as prolonged Nasdaq trading below $1, very low share price, micro-cap size, negative free cash flow, and verified recent reverse splits.
Risk indicator: 70/100
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for TRAW
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can TRAW maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can TRAW fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is TRAW likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for TRAW to reach sustainable profitability?
- •What future growth or profitability would be needed to justify TRAW's current valuation?
Essential Investment Snapshot
Wall Street Score
35
Opportunity Score
32
Market Cap
$5.4M
P/E Ratio
-0.1
EPS
$-9.42
52-Week High
$3.27
52-Week Low
$0.43
Beta
1.60
Analyst Target
$1.00
Shares Outstanding
8.4M
Total Revenue
$2.8M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$-0.63
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for TRAW
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on TRAW.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Portfolio of novel oral small molecule antiviral candidates.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and dependence on additional capital.
- −Clinical trial failure or regulatory rejection.
- −Diluted weighted-average shares increased 1164.1% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
60
Jul 24, 2026
Change
-25.1
points
Current Score
35
Oct 1, 2026
Category Changes
TRAW decreased 25.1 points because Revenue declined by 2.5 points, Asset declined by 8.9 points, Valuation declined by 85 points.
Negative Contributors
- − Revenue declined by 2.5 points
- − Asset declined by 8.9 points
- − Valuation declined by 85 points
- − Buffett declined by 10.3 points
Projected Score
Projected Score
31
Projected Change
-3.6 points
Preliminary comparable-period financial changes suggest decline of approximately 3.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.35
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +1134.5%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.8M | $226K | $226K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | — | $0.00 | $12K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | — | $2.8M | $214K | $226K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | — | $12.1M | $130.3M | $11.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | — | $8.5M | $12.3M | $9.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | — | $20.7M | $49.6M | $20.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | — | -$17.8M | -$166.5M | -$20.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | — | -$17.9M | -$49.3M | -$20.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | — | $9.2M | -$166.5M | -$18.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | — | $9.2M | -$54.7M | -$18.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | — | $0.83 | $-35.21 | $-22.57 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 10.64M | 8.23M | 1.55M | 840K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 10.64M | 8.38M | 1.55M | 840K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.16
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
-76.0%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included EPS growth. Pressure indicators included revenue growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 100.0%. EPS increased 45.5%. Cash declined 76.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyRumor Mill · TRAW
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial